Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab with CAPEOX and Celecoxib in Rectal Cancer
NCT05731726Phase 2Recruiting
- Sponsor
- Zhejiang University
- Start
- Feb 2023
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of serplulimab in rectal cancer, sponsored by Zhejiang University. Primary endpoint: Pathological complete response rate at 1 year. Started Feb 2023; status: recruiting.
02
Drugs
serplulimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT05731726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05731726.